Sign In
Buy FLGT
$18.14
-0.560 (-2.99%)
At Close: Jun 03, 2026
Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
07:20am, Wednesday, 21'st Feb 2024
Fulgent Genetics spent the past 2 years digesting the Covid cliff, which wiped out 80% of its market capitalization since the 2021 peak. The company is about to hit an inflection point, as 2024 will b
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
08:31am, Friday, 09'th Feb 2024
Testing offers CBR families the opportunity to proactively seek additional information about their child's health TRUMBULL, Conn. and EL MONTE, Calif.
The 3 Best Digital Health Stocks for Personalized Medicine
09:45am, Saturday, 25'th Nov 2023
If you're searching for digital health stocks to add to your portfolio, look no further. Technological innovation is leading to the increased digitalization and personalization of healthcare.
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
04:30pm, Tuesday, 14'th Nov 2023
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a the
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
04:05pm, Friday, 03'rd Nov 2023
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a the
Fulgent Genetics, Inc. (FLGT) Q3 2023 Earnings Call Transcript
12:22pm, Friday, 03'rd Nov 2023
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2023 Earnings Call Transcript November 3, 2023 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Brandon Perthuis - CCO Paul Kim - CFO Lawr
Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates
09:47am, Friday, 03'rd Nov 2023
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to earnings of $0.32 per share a year ago.
Fulgent Reports Third Quarter 2023 Financial Results
07:00am, Friday, 03'rd Nov 2023
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a the
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
08:00am, Wednesday, 25'th Oct 2023
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a the
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
08:00am, Tuesday, 17'th Oct 2023
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a the
Fulgent Genetics: Navigating Post-COVID Growing Pains
05:06pm, Thursday, 21'st Sep 2023
Fulgent Genetics saw robust Q2 revenue growth at $68M but struggled with a GAAP loss of $11.2M, suggesting strategic investments. The firm boasts significant liquidity ($846.8M), allowing for potentia
Fulgent Genetics, Inc. (FLGT) Q2 2023 Earnings Call Transcript
10:33am, Friday, 04'th Aug 2023
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q2 2023 Earnings Conference Call August 4, 2023 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates
09:47am, Friday, 04'th Aug 2023
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to earnings of $0.78 per share a year ago.
Fulgent Reports Second Quarter 2023 Financial Results
07:00am, Friday, 04'th Aug 2023
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a the
Fulgent Genetics: Post-Pandemic Devaluing Appears Overdone
02:00pm, Saturday, 29'th Jul 2023
Fulgent Genetics is a technology-driven company focused on clinical diagnostics and therapeutics, with recent expansion into precision medicine. FLGT's stock presents mixed signals with potential unde
